Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/209564
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Boqué, Concepción | - |
dc.contributor.author | Sánchez Ramón, Silvia | - |
dc.contributor.author | Córdoba, Raúl | - |
dc.contributor.author | Moreno, Carol | - |
dc.contributor.author | Cabezudo, Elena | - |
dc.date.accessioned | 2024-04-09T15:06:35Z | - |
dc.date.available | 2024-04-09T15:06:35Z | - |
dc.date.issued | 2023-10-04 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | http://hdl.handle.net/2445/209564 | - |
dc.description.abstract | A Delphi-based survey was designed to assess the opinions of clinical hematologists (n = 17) and clinical immunologists (n = 18) from across Spain on secondary immunodeficiencies (SID) in the management of oncohematological patients. There was 100% agreement on the need to have available guidelines for the management of immunodeficiency in hematological patients; to perform a baseline immunological evaluation in patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), lymphoma and hematopoietic stem cell transplantation (HSCT) recipients; and to quantify serum IgG, IgA and IgM levels when SID is suspected. More than 90% agreed on the need for active immunization against seasonal influenza and H1N1, pneumococcus and Haemophilus influenzae. There was a consensus on the monitoring of IgG levels every 3 months (83%) and the need to have available a clinical protocol for the use of IVIG in the management of SID (94%), to monitor trough IgG levels to determine the correct IVIG dose (86%) and to discontinue IVIG after the recovery of IgG levels after 12 months of follow-up (77%). The findings of the present survey may be useful recommendations for hematologists and immunologists to improve the management of SID in daily practice. | - |
dc.format.extent | 14 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/jcm12196356 | - |
dc.relation.ispartof | Journal of Clinical Medicine, 2023, vol. 12, num. 19 | - |
dc.relation.uri | https://doi.org/10.3390/jcm12196356 | - |
dc.rights | cc by (c) Boqué, Concepción et al, 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Malalties hematològiques | - |
dc.subject.classification | Resposta immunitària | - |
dc.subject.other | Hematologic diseases | - |
dc.subject.other | Immune response | - |
dc.title | Current Approach in the Management of Secondary Immunodeficiency in Patients with Hematological Malignancies: Spanish Expert Consensus Recommendations | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2024-04-04T08:27:30Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37835000 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jcm-12-06356.pdf | 670.38 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License